These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 18574557)

  • 1. Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors.
    Lorusso P; Heath EI; McGreivy J; Sun YN; Melara R; Yan L; Malburg L; Ingram M; Wiezorek J; Chen L; Pilat MJ
    Invest New Drugs; 2008 Oct; 26(5):455-62. PubMed ID: 18574557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
    Kotasek D; Tebbutt N; Desai J; Welch S; Siu LL; McCoy S; Sun YN; Johnson J; Adewoye AH; Price T
    BMC Cancer; 2011 Jul; 11():313. PubMed ID: 21791058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer.
    De Boer RH; Kotasek D; White S; Koczwara B; Mainwaring P; Chan A; Melara R; Ye Y; Adewoye AH; Sikorski R; Kaufman PA
    Breast Cancer Res Treat; 2012 Aug; 135(1):241-52. PubMed ID: 22872523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.
    Benjamin RS; Schöffski P; Hartmann JT; Van Oosterom A; Bui BN; Duyster J; Schuetze S; Blay JY; Reichardt P; Rosen LS; Skubitz K; McCoy S; Sun YN; Stepan DE; Baker L
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):69-77. PubMed ID: 20838998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors.
    Rosen PJ; Sweeney CJ; Park DJ; Beaupre DM; Deng H; Leitch IM; Shubhakar P; Zhu M; Oliner KS; Anderson A; Yee LK
    Clin Cancer Res; 2010 May; 16(9):2677-87. PubMed ID: 20406832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer.
    Blumenschein GR; Reckamp K; Stephenson GJ; O'Rourke T; Gladish G; McGreivy J; Sun YN; Ye Y; Parson M; Sandler A
    Clin Cancer Res; 2010 Jan; 16(1):279-90. PubMed ID: 20028752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors.
    Fujisaka Y; Yamada Y; Yamamoto N; Shimizu T; Fujiwara Y; Yamada K; Tamura T; Watanabe H; Sun YN; Bass MB; Seki M
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):935-43. PubMed ID: 20107802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours.
    Price TJ; Lipton L; McGreivy J; McCoy S; Sun YN; Rosenthal MA
    Br J Cancer; 2008 Nov; 99(9):1387-94. PubMed ID: 18971935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.
    Blumenschein GR; Kabbinavar F; Menon H; Mok TSK; Stephenson J; Beck JT; Lakshmaiah K; Reckamp K; Hei YJ; Kracht K; Sun YN; Sikorski R; Schwartzberg L;
    Ann Oncol; 2011 Sep; 22(9):2057-2067. PubMed ID: 21321086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
    Rosen LS; Kurzrock R; Mulay M; Van Vugt A; Purdom M; Ng C; Silverman J; Koutsoukos A; Sun YN; Bass MB; Xu RY; Polverino A; Wiezorek JS; Chang DD; Benjamin R; Herbst RS
    J Clin Oncol; 2007 Jun; 25(17):2369-76. PubMed ID: 17557949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
    Schlumberger MJ; Elisei R; Bastholt L; Wirth LJ; Martins RG; Locati LD; Jarzab B; Pacini F; Daumerie C; Droz JP; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Sherman SI
    J Clin Oncol; 2009 Aug; 27(23):3794-801. PubMed ID: 19564535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
    Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
    Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.
    Lu JF; Claret L; Sutjandra L; Kuchimanchi M; Melara R; Bruno R; Sun YN
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1151-8. PubMed ID: 20872145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate.
    Sawaki A; Yamada Y; Komatsu Y; Kanda T; Doi T; Koseki M; Baba H; Sun YN; Murakami K; Nishida T
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):961-7. PubMed ID: 19690858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.
    Venkatakrishnan K; Rader M; Ramanathan RK; Ramalingam S; Chen E; Riordan W; Trepicchio W; Cooper M; Karol M; von Moltke L; Neuwirth R; Egorin M; Chatta G
    Clin Ther; 2009; 31 Pt 2():2444-58. PubMed ID: 20110052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
    Machiels JP; Staddon A; Herremans C; Keung C; Bernard A; Phelps C; Khokhar NZ; Knoblauch R; Parekh TV; Dirix L; Sharma S
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):729-37. PubMed ID: 25100135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.
    Tan AR; Gibbon DG; Stein MN; Lindquist D; Edenfield JW; Martin JC; Gregory C; Suttle AB; Tada H; Botbyl J; Stephenson JJ
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1635-43. PubMed ID: 23636448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
    Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
    Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients.
    Salem AH; Yang J; Graham A; Patnaik A; Holen K; Pradhan R; Xiong H
    Anticancer Res; 2014 Apr; 34(4):2001-6. PubMed ID: 24692738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours.
    Hong DS; Kurzrock R; Mulay M; Rasmussen E; Wu BM; Bass MB; Zhong ZD; Friberg G; Rosen LS
    Oncotarget; 2014 Nov; 5(22):11154-67. PubMed ID: 25525888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.